<DOC>
	<DOCNO>NCT02594761</DOCNO>
	<brief_summary>The primary objective study demonstrate pharmacokinetic similarity Mylan trastuzumab ( Hercules ) versus EU-approved Herceptin® US-licensed Herceptin® pharmacokinetic similarity EU-approved Herceptin® versus US-licensed Herceptin® 8 mg/kg single dose administer intravenous infusion 90 minute healthy male subject base equivalence criterion AUC0-∞ , AUC0-last , Cmax least square mean ratio bound within 90 % confidence interval , 80.00 % - 125.00 % . Three similarity assessment perform , 1 ) Hercules vs. EU-approved Herceptin® , 2 ) Hercules vs. US-licensed Herceptin® 3 ) EU-approved Herceptin® vs. US-licensed Herceptin® . Secondary objective include pharmacokinetic assessment similarity Hercules , EU-approved Herceptin® US-licensed Herceptin® λz , tmax t1/2 along assessment safety ( include immunogenicity ) local tolerance .</brief_summary>
	<brief_title>Phase 1 Study Trastuzumab Administered Single Intravenous Infusion</brief_title>
	<detailed_description>All subject check clinical facility day prior dose . On study day 1 , subject receive either single i.v . infusion 8 mg/kg BW 250 mL normal saline 90 minute period Mylan trastuzumab ( Hercules ) , EU-approved Herceptin® , US-licensed Herceptin® . Dosing occur follow overnight fast least 8 hour . On day dosing , subject fast first 3 hour start infusion receive standard meal approximately 3 , 6 9 hour post-dose . In study period , blood sample collect immediately prior dose administration ( 0 hour ) 45 90 minute ( prior end infusion ) . Blood sample collect post-dose 3 , 6 , 9 , 24 48 hour , relative start infusion . The subject allow leave clinical facility 48-hour blood sample collection . Subjects return clinical facility schedule blood sample collection post-dose Day 5 , 8 , 11 , 15 , 22 , 29 , 43 , 57 , 71 . Serum sample store −80°C ± 15°C shipment analysis . Blood sample anti-drug antibody ( ADA ) collect prior dose Day 1 Day 71 . Blood sample C-reactive protein ( CRP ) obtain Screening , prior dose 3 , 24 48 hour post-dose Day 8 71 . Blood sample analysis immunoglobulin collect prior dose Day 1 Day 8 71 .</detailed_description>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>healthy adult subject , age 18 55 year old able understand procedure , agree participate willing give inform consent history significant disease use medication 7 day prior start study participation clinical trial within 30 day start study</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>